Current Research Studies

Cancer – AGCT1531: A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors

Condition or Therapy:

Germ Cell Tumors


Cancer and Blood Disorders, Germ Cell Tumor, Ovarian Cancer, Testicular Cancer, Teratoma, Carboplatin, Cisplatin
Study Number: AGCT1531

What is the goal of this study?

The purpose of this study is to see if monitoring subjects with low-risk germ cell tumors after their tumor is removed is as effective as following surgery with chemotherapy and/or more surgery.

The overall goal of the study is to compare the effects, good and/or bad, of carboplatin with cisplatin on people with standard-risk germ cell tumors to find out which is better.

Who can join the study?

This study may be a good fit for individuals with a low-risk or standard-risk germ cell tumor. For more information about study eligibility, read more about this study on

What will happen if my child takes part in this study?

Standard therapy for low-risk germ cell tumors can include surgery, followed by chemotherapy and/or more surgery. In this study, patients with low-risk tumors will not get further treatment once the tumore has been surgically removed. Instead, they will be closely monitored with frequent blood tests and scans to see if the tumor comes back (relapses). Participants will be monitored to see if it spreads to other parts of the body. Monitoring includes blood tests, X-rays and scans to monitor if the tumor has returned.

For patients with standard-risk germ cell tumors, patients will receive 1 of 2 different treatment plans. The treatment plan that you receive is decided by a process called randomization. Participants will be randomized to receive chemotherapy treatment on one of the following arms: 

  • Arm A: bleomycin, etoposide and carboplatin (experimental)
  • Arm B: bleomycin, etoposide and cisplatin (standard)

Who can I contact for more information?

To learn more, call 206-884-1214 or email the study coordinator.

Study Location(s):

Seattle Children's Main Hospital Campus

Principal Investigator:

Dr. Douglas Hawkins